Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

NCT02861573 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

1200

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-Resistant Prostate Cancer

Interventions

BIOLOGICAL: Pembrolizumab 200 mg
DRUG: Olaparib 400 mg
DRUG: Docetaxel 75 mg/m^2
DRUG: Prednisone 5 mg
DRUG: Enzalutamide 160 mg
OTHER: Dexamethasone 8 mg
DRUG: Olaparib 300 mg
DRUG: Abiraterone acetate 1000 mg
DRUG: Lenvatinib
BIOLOGICAL: Pembrolizumab/Vibostolimab coformulation
DRUG: Carboplatin
DRUG: Etoposide
BIOLOGICAL: Belzutifan 120mg

Sponsor

Merck Sharp & Dohme LLC